Wholesale
Wholesale pricing available
Qualify for automatic discounts at checkout when your order of wholesale eligible items hits a volume threshold.
$2,000+15% off$4,000+20% off$6,000+25% off$10,000+40% offFull wholesale details →
$371.78$391.35
($74.36 / Item) — Save $19.57 (5% off)
In stock — dispatches within 24h, tracked
IGF-1 LR3 1mg. Used to support muscle growth, recovery, strength, and overall body composition. Lab tested, discreetly shipped across Canada.
FormatLyophilized Vial
ConcentrationDepends on reconstitution with BAC water
Pack Size Selected: 5 Pack
Pay with Interac e-Transfer or Crypto
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
IGF-1 LR3 is a synthetic long acting analogue of Insulin Like Growth Factor 1 (IGF-1), engineered with two structural modifications that substantially alter its pharmacokinetic profile from native IGF-1. An arginine substitution at position 3 and a 13 amino acid N terminal extension that together produce a compound with dramatically reduced insulin like growth factor binding protein (IGFBP) affinity and a significantly extended half-life. Hudson Science’s formulation supplies 1mg as a lyophilized vial, a standard research unit for IGF analogues where precise low concentration handling is critical. Preserving peptide structural integrity and potency across storage conditions until reconstitution.
The structural modifications defining IGF-1 LR3 produce a pharmacological profile that is distinctly more potent and longer acting than native IGF-1 in research contexts. Native IGF-1’s extensive IGFBP binding sequesters a significant fraction of administered compound in circulation, reducing receptor available concentration. IGF-1 LR3’s reduced IGFBP affinity, estimated at approximately 1000 fold lower than native IGF-1 maintains a substantially higher free bioavailable fraction per administered dose, with the N-terminal extension contributing additional receptor activation enhancement. The combined effect produces an estimated half-life of approximately 20–30 hours compared to native IGF-1’s 12–15 hours. A meaningful research advantage for protocols examining sustained IGF-1 receptor activation without the frequent administration that native IGF-1’s IGFBP-sequestered profile would require.
IGF-1 LR3 and IGF-DES represent complementary rather than interchangeable research tools within CSD’s IGF analogue range despite both operating through reduced IGFBP binding mechanisms. IGF-DES achieves IGFBP reduction through N-terminal truncation, removing the first three amino acids, producing very high local receptor potency with a shorter active window suited to localized tissue research. IGF-1 LR3’s N-terminal extension and arginine substitution produce sustained systemic IGF-1 receptor activation with a longer half-life suited to research examining extended anabolic pathway stimulation, satellite cell recruitment, skeletal muscle hypertrophy mechanisms, and systemic IGF-1 axis activity across multiple tissue types simultaneously.
Hudson Science formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD stocks both IGF-1 LR3 and IGF-DES as complementary IGF analogue research compounds, alongside the full GH secretagogue range including GHRP-2, GHRP-6, Ipamorelin, Hexarelin, Sermorelin, Tesamorelin, CJC-1295, and rHGH. Giving researchers access to the complete growth hormone and IGF axis research compound family from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.
Commonly researched alongside IGF-DES and HGH in comparative IGF receptor binding and anabolic signaling studies. Browse CSD’s full peptide range for complete sourcing.
IGF-1 LR3, or Long R3 Insulin Like Growth Factor-1, is a synthetic analogue of IGF-1 engineered to alter its interaction with IGF binding proteins. The molecule contains an arginine substitution at position 3 and an additional 13 amino acid extension at the N-terminus, producing an 83 amino acid analogue. This product contains 1mg of lyophilized IGF-1 LR3 in a single vial for laboratory research.
IGF-1 LR3 is primarily investigated in research involving IGF-1 receptor signaling, cellular proliferation, differentiation, protein synthesis, skeletal muscle biology, tissue growth, and metabolic signaling. Because the analogue interacts less strongly with IGF binding proteins than native IGF-1, it is frequently used in experimental systems where researchers want more sustained access to IGF receptor signaling.
Native human IGF-1 contains 70 amino acids and circulates extensively bound to IGF-binding proteins. IGF-1 LR3 contains an arginine substitution at position 3 plus a 13 amino acid N-terminal extension. These modifications greatly reduce its affinity for several IGF-binding proteins while retaining activity at the IGF-1 receptor, giving LR3 a distinct biological profile in experimental systems.
IGF-1 LR3 and IGF-DES are different modified forms of IGF-1. LR3 is longer than native IGF-1, containing 83 amino acids due to its N-terminal extension and Arg3 substitution. IGF-DES is shorter, containing 67 amino acids because the first three residues of native IGF-1 have been removed. Both have reduced interaction with IGF binding proteins, but their structures and experimental pharmacology differ.
Yes! This batch is HPLC tested to verify IGF-1 LR3 identity and content accuracy at 1mg per vial. A certificate of analysis is available
